Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabrina Bacci

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Vaccine|May 4, 2024
Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in EuropeMarine Maurel, Clara Mazagatos, Luise Goerlitz, et al.
Influenza and Other Respiratory Viruses|May 21, 2025
COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care NetworkCharlotte Laniece Delaunay, Nuno Verdasca, Susana Monge, et al.
Influenza and Other Respiratory Viruses|November 11, 2024
Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024Lore Merdrignac, Charlotte Laniece Delaunay, Nuno Verdasca, et al.
Influenza and Other Respiratory Viruses|March 9, 2025
Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024Liliana Antunes, Madelyn Rojas-Castro, Marcos Lozano, et al.
Vaccine|July 6, 2024
Corrigendum to "Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: results from the VEBIS primary care test-negative design study, September 2023-January 2024" [Vaccine 42(19) (2024)]Charlotte Laniece Delaunay, Aryse Melo, Marine Maurel, et al.
JAMA Network Open|June 15, 2026
COVID-19 Vaccine Effectiveness Among Older AdultsCharlotte Laniece Delaunay, Alberto Mateo-Urdiales, Gloria Pérez-Gimeno, et al.
International Journal of Epidemiology|June 19, 2025
The potential bias introduced into COVID-19 vaccine effectiveness studies at primary care level due to the availability of SARS-CoV-2 tests in the general populationCharlotte Lanièce Delaunay, Baltazar Nunes, Susana Monge, et al.
Vaccine|June 5, 2024
Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024Charlotte Laniece Delaunay, Aryse Melo, Marine Maurel, et al.
Pediatrics|April 5, 2026
Influenza Vaccine Effectiveness in European Primary Care Pediatric Practices: 2022-2024Héloïse Lucaccioni, Marine Maurel, Gloria Pérez-Gimeno, et al.
Vaccine|December 26, 2024
Relative effectiveness of the second booster COVID-19 vaccines against laboratory confirmed SARS-CoV-2 infection in healthcare workers: VEBIS HCW VE cohort study (1 October 2022-2 May 2023)Camelia Savulescu, Albert Prats-Uribe, Kim Brolin, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Vaccine|May 4, 2024
Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in EuropeMarine Maurel, Clara Mazagatos, Luise Goerlitz, et al.
Influenza and Other Respiratory Viruses|May 21, 2025
COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care NetworkCharlotte Laniece Delaunay, Nuno Verdasca, Susana Monge, et al.
Influenza and Other Respiratory Viruses|November 11, 2024
Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024Lore Merdrignac, Charlotte Laniece Delaunay, Nuno Verdasca, et al.
Influenza and Other Respiratory Viruses|March 9, 2025
Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024Liliana Antunes, Madelyn Rojas-Castro, Marcos Lozano, et al.
Vaccine|July 6, 2024
Corrigendum to "Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: results from the VEBIS primary care test-negative design study, September 2023-January 2024" [Vaccine 42(19) (2024)]Charlotte Laniece Delaunay, Aryse Melo, Marine Maurel, et al.
JAMA Network Open|June 15, 2026
COVID-19 Vaccine Effectiveness Among Older AdultsCharlotte Laniece Delaunay, Alberto Mateo-Urdiales, Gloria Pérez-Gimeno, et al.
International Journal of Epidemiology|June 19, 2025
The potential bias introduced into COVID-19 vaccine effectiveness studies at primary care level due to the availability of SARS-CoV-2 tests in the general populationCharlotte Lanièce Delaunay, Baltazar Nunes, Susana Monge, et al.
Vaccine|June 5, 2024
Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024Charlotte Laniece Delaunay, Aryse Melo, Marine Maurel, et al.
Pediatrics|April 5, 2026
Influenza Vaccine Effectiveness in European Primary Care Pediatric Practices: 2022-2024Héloïse Lucaccioni, Marine Maurel, Gloria Pérez-Gimeno, et al.
Vaccine|December 26, 2024
Relative effectiveness of the second booster COVID-19 vaccines against laboratory confirmed SARS-CoV-2 infection in healthcare workers: VEBIS HCW VE cohort study (1 October 2022-2 May 2023)Camelia Savulescu, Albert Prats-Uribe, Kim Brolin, et al.
Pageof 5